Interview with Robert Karl, Managing Director, MSD Russia
You have been in Russia now for a bit less than a year, having come from the former Schering-Plough’s Hungary office to run the Russian MSD affiliate. In our conversation…
Address: MSD Pharmaceuticals, Shabolovka 10, 119049, Moscow,Russia
Tel: +7 495 916-7100
Web: http://www.merck.com/index.html
About MSD
Today’s MSD is a global healthcare leader working to help the world be well. Through our medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching programs that donate and deliver our products to the people who need them. For more information, visit www.msd.com. MSD is a tradename of Merck & Co., Inc., with headquarters in Whitehouse Station, N.J., U.S.A.
About MSD in Russia
In Russia, MSD is committed of developing innovative, first-in-class products, improving health and saving lives of Russian citizens. MSD in Russia is dedicated to science and scientific excellence, focusing on clinical research activities in the country. MSD products have been available in Russia for many years. In Russia, the company was recently renamed into MSD Pharmaceuticals LLC.
About MSD in Emerging Markets
In the Emerging Markets, MSD is currently ranked #5 by market share among multinational companies (IMS Health 2009); this ranking includes Asia Pacific, Latin America, Eastern Europe, Middle East and Africa. For MSD, Emerging Markets are defined as the following regions and countries: Asia Pacific, China, Latin America, Brazil, Eastern Europe and Middle East and Africa, including Russia.
MSD’s current portfolio and R&D focus are complementary to important disease areas with pressing public health issues in Emerging Markets: infectious diseases, vaccinations, cardiovascular disease, diabetes, women’s health and respiratory.
You have been in Russia now for a bit less than a year, having come from the former Schering-Plough’s Hungary office to run the Russian MSD affiliate. In our conversation…
Although Russian authorities received heavy criticism for approving the Sputnik V vaccine prior to the completion of Phase III clinical trials, the jab is increasingly being seen as a viable…
Russia has announced that a domestically developed COVID-19 vaccine has been approved by its health authorities, the first such approval globally. However, with large-scale Phase III trials having not yet…
Below is a selection of top stories in Russian pharma from recent months, ranging from proposed changes in legislation, labelling system updates, priorities set forth by the country’s manufacturing association…
Russia is facing a drug shortage crisis which is having a particular impact on patients with life-threatening conditions. A combination of geopolitical and bureaucratic issues are restricting the flow of…
In the latest twist in the ongoing story of Russian interference in the US presidential elections of 2016, it has emerged that Russian internet trolls and automated bots spread misinformation…
In the United States, Johnson & Johnson has an image of being very close to people. Americans grow up with this company — from baby shampoo, to Tylenol when they…
You took over this organization just three months ago, having previously headed businesses in industries as diverse as retail, food, and automobiles. What drew you to Alliance Healthcare Russia? Do…
The ARPM was founded in 2002, and you were its director from 2002-2004, before leaving for a post at the Roszdravnadzor. You’ve since rejoined as director since 2007. The organization…
When Focus Reports prepared a report on the French pharmaceutical industry in 2009/10, we found that the head of the main multinational pharmaceutical association had taken a career path quite…
The U.S. and Russia have a long history of trade, and you have personally been with the American Chamber of Commerce in Russia since 2001. Can you give a brief…
The primary objectives of this association are to promote Russia as a clinical trial destination, optimize the regulatory and legislative environment, and promote the interests of ACTO members. Can you…
You have said that AstraZeneca intends to be “in Russia for Russia” and the company has recently announced a large-scale investment in this country, financing a $150Mn domestic facility in…
See our Cookie Privacy Policy Here
